Neo-adjuvant Pembrolizumab in dMMR/ POLE-EDM Uterine Cancer Patients: a Feasibility Study

NCT04262089 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Uterine Cancer

Interventions

DRUG: Pembrolizumab (Keytruda)

Sponsor

University Medical Center Groningen

Collaborators

[object Object]